Ramucirumab (brand name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone...
14 KB (1,302 words) - 07:55, 1 July 2024
Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell factor Kinase...
121 KB (13,799 words) - 18:32, 22 August 2024
Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell factor Kinase...
31 KB (3,430 words) - 05:24, 28 August 2024
the above are treated with second-line chemotherapeutics docetaxel and ramucirumab. Integrating palliative care (medical care focused on improving symptoms...
90 KB (9,784 words) - 14:55, 21 June 2024
Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell factor Kinase...
13 KB (1,177 words) - 00:03, 12 August 2024
Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell factor Kinase...
68 KB (6,007 words) - 22:36, 15 August 2024
antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment...
57 KB (4,072 words) - 11:12, 5 August 2024
Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell factor Kinase...
42 KB (3,935 words) - 04:01, 30 April 2024
Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell factor Kinase...
149 KB (15,717 words) - 06:34, 13 August 2024
Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell factor Kinase...
73 KB (6,440 words) - 06:25, 18 August 2024